Today's MarketStats on Healthcare and Biotechnology companies include: CardioVascular Bio Therapeutics, Inc. (OTCBB: CVBT), Boston Scientific Corp. (NYSE: BSX), Medtronic Inc. (NYSE: MDT), Cardium Therapeutics Inc. (AMEX: CXM) and Genentech Inc. (NYSE: DNA).
CardioVascular Bio Therapeutics, Inc. (OTCBB: CVBT) CardioVascular Bio Therapeutics, Inc., is a development stage biopharmaceutical company that focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company is headquartered in Las Vegas, NV.
CVBT has bucked the overall Market trend, posting a 10.91% 52 week return. As many Markets were experiencing heavy losses in January, CVBT had a significant increase in their share price and appears to have established a new and higher trading range from a technical standpoint. The new “resistance level” is at the $1.20 share price with upside selling pressure coming in around the $1.40 range. If CVBT can trade through this range and close higher, it could be seen as a bullish indicator.
The inspiring yearly return was helped by their breakthrough angiogenesis therapy. This therapy is currently featured in the February 2008 issue of “Reader’s Digest.” The article, titled, “Heart Hope” by Lisa Collier Cool, refers to CVBT’s therapy as a “new lease on life” for patients suffering from severe coronary heart disease who do not have any other viable treatment options. This exposure and the technology behind it are a huge positive for the company.
To view a complete profile on CardioVascular Bio Therapeutics, Inc., visit our financial courier at StockUpTicks.com
Boston Scientific Corp.(NYSE: BSX) Boston Scientific Corporation engages in the development, manufacture, and marketing of medical devices that are used in interventional medical specialties worldwide. The company offers its products in three groups: Cardiovascular, Endosurgery, and Neuromodulation.
This past Tuesday, BSX announced that a U.S. District Court jury in Marshall, Texas has reached a verdict in a patent infringement suit brought against the Company by Dr. Bruce Saffran. No injunction was requested, but the jury awarded damages of $431 million.
With a 26% drop over the past year and a negative net income, volatility could continue for the foreseeable future.
Medtronic Inc. (NYSE: MDT) Medtronic, Inc. is engaged in medical technology, alleviating pain, restoring health, and extending life for people around the world. The company was founded in 1949 and is headquartered in Minneapolis, Minnesota.
MDT is consistently one of the most efficient companies in the Medical Equipment & Supplies industry. With a Return on Assets, Revenues per Employee, and Return on Equity of 14.50%, $363,981.00, and 26.32% respectively, they are among the most effective companies in the industry.
Based on its gross margin, operating margin, and net margin, MDT converts a larger percentage of its revenues to profits than most other companies in the Medical Equipment & Supplies industry. Furthermore, the company is profitable with an operating margin of 28.11%.
Cardium Therapeutics Inc. (AMEX: CXM) Cardium Therapeutics, Inc. (Cardium) is a medical technology company primarily focused on the development and commercialization of biologic therapeutics and medical devices for cardiovascular and ischemic disease. The company was founded in 2003 and is based in San Diego, California.
Although earnings at CXM grew over the last twelve months, they failed to keep pace with the growth in revenues. This may mean that the company is becoming less efficient at using its resources. However, this result was better than that of the average company in the Biotechnology & Drugs industry.
While CXM has little or no debt and, thus, little financial risk, it has a cost structure that eats up a percentage of its revenues that is among the highest of any company in the Biotechnology & Drugs industry. To make matters worse, the company is losing money on an operating basis.
Genentech Inc. (NYSE: DNA) is a biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for unmet medical needs. The Company manufactures and commercializes multiple biotechnology products, and receives royalties from companies that are licensed to market products based on its technology.
Yesterday, Genentech traded higher by .93 cents per share to $70.85 after releasing positive data from the AVADO study, with Avastin measuring progression-free survival (PFS) in patients with metastatic breast cancer. The company said the Food and Drug Administration is schedule to rule Feb. 23 on an approval to use Avastin in combination with chemotherapy to treat breast cancer.
Earnings growth at DNA outpaced revenue growth over the trailing twelve months. This is a trend that is not sustainable if profits are to continue to grow at this rate. However, this result was better than that of the average company in the Biotechnology & Drugs industry.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report.
This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor, analyst or licensed broker dealer and this report is not investment advice. MP has been granted twenty thousand restricted shares of CVBT common stock by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment